サンプル依頼リスト カート
  • English
  • Korean
表紙：院内感染の世界市場-2023年～2030年
市場調査レポート
商品コード
1297825

院内感染の世界市場-2023年～2030年

Global Hospital Acquired Infections Market - 2023-2030

出版日
ページ情報
英文 195 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
院内感染の世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界の院内感染市場は2022年に144億米ドルに達し、2030年には195億米ドルに達するなど、有利な成長が予測されています。世界の院内感染市場は、2023年から2030年の予測期間中に3.8%のCAGRを示すと予測されています。入院患者の増加と新薬の臨床試験の増加が、院内感染市場動向の需要を押し上げています。

患者がヘルスケアセンターや医師から投薬を受けると、医療関連感染とも呼ばれる院内感染に罹患する可能性があります。患者の肺、皮膚、血液、消化管、尿路のすべてが感染する可能性があります。敗血症、手術部位感染、カテーテル関連尿路感染などはヘルスケア関連感染の一例です。これらの病気の治療には、抗ウイルス薬や抗菌薬が使用されます。

院内感染症市場のスコープは、抗菌薬、抗ウイルス薬、抗真菌薬などの薬剤タイプで構成され、院内感染症市場シェアを拡大しています。病院感染症の世界市場は、研究開発の増加や各国における今後の医療承認などの要因により拡大しており、病院感染症市場の成長にも明るい見通しが生まれています。

市場力学

院内感染発生率の増加が院内感染市場の成長を牽引

米疾病対策センター（CDC）によると、HAIはアメリカの病院だけで年間170万人の疾病と99,000人の死亡を引き起こすと予想されています。これらの疾患のうち、尿路感染症が医療関連感染症全体の32％、手術部位感染症が22％、肺炎（肺感染症）が15％、血流感染症が14％を占めています。

さらに、カナダ公衆衛生局は2022年8月、カナダの主要学術病院に入院する患者の2％が入院中に感染症に罹患し、入院患者の3％から10％が常時、抗菌薬耐性菌に感染または保菌していると予測しました。したがって、院内感染の増加が院内感染市場を牽引しています。

意識の高まりと研究開発がメーカーに有利な機会をもたらす

ヘルスケア関連感染による高い死亡率と罹患率は、ヘルスケア業界に毎年数十億米ドルの損失をもたらしています。中心静脈ラインのモニタリング、設置、追跡、感染患者の隔離については、長年にわたって多くのガイドラインが作成されてきました。変化をもたらす唯一の方法は、すべてのヘルスケアチームが協力することです。患者や医療従事者の間で感染因子が広がるのを防ぐことが、病院で用いられる主な戦術です。

看護師は感染した患者に最初に接触することが多いため、予防には欠かせない存在です。感染予防の鍵は手洗いであり、全員が定められたガイドラインを確実に守ることです。カテーテルの固定、医療スタッフへの感染防止対策の指導、手洗い、侵襲的処置の際の無菌的手技の使用など、数多くのカテゴリー1Aの推奨事項があります。このように、これらの要因は院内感染市場規模の成長機会を生み出すと思われます。

厳しい薬価設定が市場成長の妨げに

医薬品の価格設定は、多数の企業が関与する難しいプロセスであり、費用対効果に大きな影響を与えます。価値に基づく価格設定は、医薬品の費用対効果を把握するための手法です。

価値に基づく価格設定が新しい抗菌薬のコストにどのような影響を与えるかはまだ明らかではないが、重要な決定要因は価値という概念であろう。この価値には、患者の健康に対する薬の効果だけでなく、社会に対するより広い影響や病気の健康への影響も含まれる可能性があります。したがって、上記のような要因が院内感染市場の成長を制限しています。

COVID-19の影響分析

COVID-19のパンデミックと世界各国での封鎖により、あらゆる業種の企業の財務の健全性が影響を受けています。そのため、COVID-19公衆衛生緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施基準（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な考慮事項を含むガイドラインを発表しました。

ロシア・ウクライナ紛争の影響分析

ロシアとウクライナの紛争は、この地域の主要市場企業の数が少ないことから、世界の院内感染症市場に与える影響は中程度と推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界の院内感染市場の成長にほとんど影響を与えないと予測されます。

目次

第1章 調査手法と範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響を与える要因
    • 促進要因
      • 主要企業別臨床試験の増加
      • 院内感染の増加
    • 抑制要因
      • 医薬品の厳格な価格設定
    • 機会
      • 意識の向上と研究開発
    • 影響分析

第5章 業界分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19の分析

第7章 感染の種類別

  • 胃腸感染症
  • 尿路感染症
  • 人工呼吸器関連肺炎
  • 血流感染症
  • 手術部位の感染症
  • その他

第8章 薬剤の種類別

  • 抗菌薬
    • バンコマイシン
    • ベータラクタム
    • キノロン類
    • その他
  • 抗ウイルス薬
    • アシクロビル
    • フォスカーネット
  • 抗真菌薬
    • アムホテリシンB
    • トリアゾール
  • その他
    • 駆虫薬
    • 抗原虫薬
    • 抗結核治療

第9章 エンドユーザー別

  • 病院とICU
  • 外来手術および診断センター
  • 老人ホームと助産所
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
      • その他アジア太平洋地域
  • 中東とアフリカ
    • 主要な地域固有のダイナミクス

第11章 競合情勢

  • 競合シナリオ
  • 市場ポジショニング/シェア分析
  • 合併と買収の分析

第12章 企業プロファイル

  • Merck &Co., Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Pfizer Inc.
  • AbbVie Inc.
  • AstraZeneca
  • GSK plc
  • Innoviva
  • ELI LILLY AND COMPANY
  • STERIS
  • Cipla Inc.
  • Basilea Pharmaceutica Ltd.

第13章 付録

目次
Product Code: CD429

Market Overview

The Global Hospital Acquired Infections Market reached US$ 14.4 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 19.5 billion by 2030. The global hospital acquired infections market is expected to exhibit a CAGR of 3.8% during the forecast period 2023-2030. The increasing hospital admissions and the growing clinical trials for novel drugs are driving up demand for hospital acquired infections market trends.

When a patient receives medication at a healthcare center or from a doctor, they may contract hospital-acquired infections, also known as healthcare-associated infections. The patient's lungs, skin, blood, digestive or urinary tracts could all get infected. Sepsis, surgical site infections, catheter-associated urinary tract infections and others are examples of healthcare-associated infections. Drugs that are antiviral or antibacterial are used to treat these illnesses.

The hospital acquired infections market scope comprises drug type as antibacterial drugs, antiviral drugs, antifungal drugs and others, which has increased the hospital acquired infections market share. The global market for hospital acquired infections is expanding as a result of factors including increasing research and development and their upcoming medical approvals across countries are also creating a positive outlook for the hospital acquired infections market growth.

Market Dynamics

An Increase in the Incidence of Hospital Acquired Infections Drive the Growth of the Hospital Acquired Infections Market

According to the Centers for Disease Control (CDC), HAIs are expected to cause 1.7 million illnesses and 99,000 deaths annually in American hospitals alone. Of these illnesses, urinary tract infections account for 32% of all healthcare-acquired infections, surgical site infections for 22%, pneumonia (lung infections) for 15% and bloodstream infections for 14%.

Additionally, the Public Health Agency of Canada predicted in August 2022 that 2% of patients admitted to major academic hospitals in Canada will contract an infection during their stay and that 3% to 10% of hospitalized patients will at any given time be infected with or carrying an antimicrobial-resistant organism. Hence, the growing hospital acquired infection is driving the hospital acquired infections market.

Rising Awareness and Research and Development Creates Lucrative Opportunities for Manufacturers

High mortality and morbidity rates from healthcare-associated infections cost the healthcare industry billions of dollars annually. Many guidelines for monitoring, setting up and tracking central lines and isolating infected patients have been created throughout the years. The only way to make a difference is for all healthcare teams to work together. Preventing the spread of infectious agents amongst patients and medical personnel is the main tactic used in hospitals.

Since they frequently come into contact with infected patients initially, nurses are essential to prevention. The key to preventing infections is hand washing and ensuring that everyone abides by the stated guidelines. Numerous category 1A recommendations, such as securing catheters, teaching medical staff about infection control practices, hand washing and the use of aseptic techniques during invasive procedures. Thus these factors will create opportunities for the growth of hospital acquired infections market size.

Stringent Pricing of Drugs will Hamper the Growth of the Market.

Drug pricing is a difficult process that involves numerous players and greatly affects cost-effectiveness. Pricing based on value is a technique for figuring out the cost-effective price for the medicine.

Although it is not yet clear how value-based pricing will affect the costs of new antibacterial drugs, a key determining factor will be the notion of value, which may include not only the effect of the drug on the patient's health but also its wider impact on society and the health effects of the disease. Hence these above-mentioned factors are limiting the hospital-acquired infections market's growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP) and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global hospital-acquired infections market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global hospital acquired infections market growth over the forecast period.

Segment Analysis

The global hospital acquired infections market is segmented based on infection type, drug type, end user and region.

Antibacterial drugs from the Drug Type Segment Account for 37.3% of the Market Share Owing to Rising Novel Product Launches

Antibacterial medications, also referred to as antibiotics, are a class of pharmaceuticals used to treat bacterial infections. Antibiotics focus on specific bacteria or bacterial processes, like protein synthesis or cell wall construction. The nature and extent of the ailment will determine the exact treatment and dosage. Antibacterial medications can be administered intravenously, topically, or orally, among other ways.

Recently, many new antimicrobial drugs with new targets have hit the market, albeit others are still awaiting FDA approval. Macrocyclic antibiotics, more recent cephalosporins, glycopeptides, carbapenems, pleuromutilin and other ones are a few of them. Today, one of the antibiotic classes most frequently recommended for the treatment of bacterial infections is lactams. By blocking PBPs, which are necessary for cross-linking in cell wall production, they prevent bacterial growth.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share Owing to the Strong Presence of Major Players and Increasing Technological Advancements

Manufacturers have chances to expand their operations in this region because of the rising demand for hospital-acquired infections for advancements in North America. The area has many producers and suppliers and its rapid economic development has raised industrial production of hospital-acquired infections, which has increased the demand.

North America has a large number of producers and suppliers, and as a result of the swift economic development of the area, industrial production has increased, fueling the demand for hospital acquired infections.

Rising new drug or infection types will drive market growth. Growth is also fueled by rising technological advancements, regulatory approvals and novel product launches. Researchers are becoming more aware of various kinds of diagnostic approaches for infectious disorders, leading to the expansion of the market in this region. These factors show the dominance of North America.

Competitive Landscape

The major global players in the hospital acquired infections market include: F Hoffmann-la Roche Ltd, Pfizer Inc., AbbVie Inc., AstraZeneca, GSK plc, Innoviva, Eli Lilly and Company, Steris, Cipla Inc. and Basilea Pharmaceutica Ltd. among others.

Why Purchase the Report?

  • To visualize the global hospital-acquired infections market segmentation based on infection type, drug type, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of hospital-acquired infections market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Hospital Acquired Infections Market Report Would Provide Approximately 53 Tables, 54 Figures and 195 Pages.

Target Audience 2023

  • Manufacturers / Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Infection Type
  • 3.2. Snippet by Drug Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Rising Clinical Trials by Key Companies
      • 4.1.1.2. Rising Incidence of Hospital-Acquired Infection
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Pricing of Drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising Awareness and Research and Development
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Infection Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 7.1.2. Market Attractiveness Index, By Infection Type
  • 7.2. Gastrointestinal Infections *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Urinary Tract Infections
  • 7.4. Ventilator-Associated Pneumonia
  • 7.5. Bloodstream Infections
  • 7.6. Surgical Site Infections
  • 7.7. Others

8. By Drug Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 8.1.2. Market Attractiveness Index, By Drug Type
  • 8.2. Antibacterial Drug *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Vancomycin
    • 8.2.4. Beta-Lactams
    • 8.2.5. Quinolones
    • 8.2.6. Others
  • 8.3. Antiviral Drug
    • 8.3.1. Acyclovir
    • 8.3.2. Foscarnet
  • 8.4. Antifungal Drug
    • 8.4.1. Amphotericin B
    • 8.4.2. Triazoles
  • 8.5. Others
    • 8.5.1. Antiparasitic
    • 8.5.2. Antiprotozoal
    • 8.5.3. Anti-TB Treatment

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals & ICUs *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical & Diagnostic Centers
  • 9.4. Nursing Homes & Maternity Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan

Australia

      • 10.5.6.4. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Merck & Co., Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Pfizer Inc.
  • 12.3. AbbVie Inc.
  • 12.4. AstraZeneca
  • 12.5. GSK plc
  • 12.6. Innoviva
  • 12.7. ELI LILLY AND COMPANY
  • 12.8. STERIS
  • 12.9. Cipla Inc.
  • 12.10. Basilea Pharmaceutica Ltd.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us